Law360, New York (October 17, 2008, 12:00 AM ET) -- The U.S. Food and Drug Administration has added a boxed warning to the psoriasis drug Raptiva, highlighting the risks of life-threatening infections related to use of the skin disease treatment.
The FDA said it had received reports of serious infections in patients using Raptiva, which is made by Genentech. Those infections included some that led to hospitalizations and deaths.
The new boxed warning will highlight the potential risk of opportunistic infections, including bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy, a rare brain...
FDA Adds Boxed Warning To Psoriasis Drug
To view the full article, take a free trial now.
